Develops immuno-oncology therapies using gene-edited T-cells. Focuses on creating allogeneic T-cell product candidates for various cancers. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 25% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 76% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 25% a year on average.
Sales run at $72.9M a year. A small number, but proof the product has real buyers.
A loss of $67.6M against $72.9M in annual sales.
This stock swings about 2.9 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, CLLS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CLLS is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (34/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.